KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-4280A, Lenvatinib clinical trials

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

This study is looking at a new combination of medicines for some types of cancer, called MK-4280A and pembrolizumab. It wants to see how well these medicines shrink tumours and if they help people feel better. It's a Phase 2 trial, meaning it's still in earlier stages of testing.